Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979–1987, 2007

In Table 2 of the article above, an asterisk was missing denoting a significant difference between the 1,000 mg metformin b.i.d. group and placebo. The corrected table appears on the following page. The online version reflects these changes.

Table 2—

Efficacy end points following a meal tolerance test

ParameterPlaceboSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1,000 mg b.i.d.Sitagliptin 50 mg + metformin 500 mg b.i.d.Sitagliptin 50 mg + metformin 1,000 mg b.i.d.
2-h PPG (mg/dl)       
    n 129 136 141 138 147 152 
    Baseline 276.8 ± 66.7 285.4 ± 82.8 292.7 ± 74.6 283.4 ± 81.8 291.8 ± 84.6 286.9 ± 76.2 
    Week 24 281.3 ± 88.2 233.8 ± 89.5 236.3 ± 70.8 207.0 ± 69.4 196.3 ± 72.5 170.3 ± 58.6 
    Change from baseline 0.3 (−10.4 to 11.0) −51.9 (−62.3 to −41.5) −53.4 (−63.6 to −43.2) −78.0 (−88.3 to −67.6) −92.5 (−102.6 to −82.5) −116.6 (−126.4 to −106.7) 
    Change from placebo — −52.2 (−67.1 to −37.3)* −53.7 (−68.5 to −38.9)* −78.3 (−93.1 to −63.4)* −92.8 (−107.5 to −78.1)* −116.9 (−131.4 to −102.3)* 
Glucose AUC (mg · h−1 · dl−1      
    n 127 133 144 137 149 146 
    Baseline 523.0 ± 109.4 530.2 ± 123.9 538.4 ± 116.0 532.1 ± 125.6 539.9 ± 136.7 530.0 ± 120.7 
    Week 24 533.3 ± 146.9 453.2 ± 135.3 451.3 ± 118.4 401.7 ± 120.4 383.9 ± 114.0 339.0 ± 100.4 
    Change from baseline 6.1 (−11.7 to 23.9) −78.0 (−95.4 to −60.6) −84.4 (−101.1 to −67.7) −130.8 (−147.9 to −113.6) −152.4 (−168.9 to −136.0) −192.3 (−209.0 to −175.7) 
    Change from placebo — −84.2 (−109.1 to −59.3)* −90.5 (−115.5 to −66.1)* −136.9 (−161.6 to −112.2)* −158.6 (−182.8 to −134.3)* −198.5 (−222.8 to −174.1)* 
Insulin AUC (μIU · h−1 · ml−1      
    n 119 117 130 125 126 133 
    Baseline 76.5 ± 52.9 71.2 ± 50.2 80.1 ± 56.4 84.3 ± 53.6 79.0 ± 57.2 74.9 ± 47.2 
    Week 24 75.0 ± 50.3 78.1 ± 49.3 83.1 ± 54.6 82.2 ± 51.4 86.3 ± 55.7 74.5 ± 40.6 
    Change from baseline −1.8 (−7.5 to 3.9) 5.2 (−0.6 to 11.0) 3.6 (−1.9 to 9.1) −0.4 (−6.0 to 5.2) 7.5 (2.0–13.1) −1.1 (−6.5 to 4.4) 
    Change from placebo — 7.0 (−1.2 to 15.1) 5.4 (−2.5 to 13.3) 1.4 (−6.6 to 9.4) 9.4 (1.4–17.3) 0.7 (−7.1 to 8.6) 
C-peptide AUC (ng · h−1 · ml−1125 135 143 138 146 145 
    n       
    Baseline 9.8 ± 4.3 9.8 ± 4.3 10.3 ± 4.1 10.9 ± 4.3 9.9 ± 4.3 10.1 ± 4.1 
    Week 24 9.8 ± 4.2 10.5 ± 4.0 10.2 ± 4.1 10.6 ± 4.1 10.6 ± 4.1 10.4 ± 4.1 
    Change from baseline −0.1 (−0.5 to 0.3) 0.6 (0.2–1.0) 0.0 (−0.4 to 0.4) −0.1 (−0.5 to 0.3) 0.6 (0.2–1.0) 0.3 (−0.1 to 0.7) 
    Change from placebo — 0.7 (0.1–1.3) 0.1 (−0.5 to 0.7) 0.0 (−0.6 to 0.6) 0.7 (0.1–1.3)§ 0.4 (−0.2 to 1.0) 
Insulin AUC/glucose AUC 117 115 128 121 125 130 
    n       
    Baseline 0.16 ± 0.14 0.15 ± 0.12 0.16 ± 0.12 0.18 ± 0.15 0.16 ± 0.14 0.16 ± 0.12 
    Week 24 0.16 ± 0.14 0.19 ± 0.13 0.20 ± 0.15 0.23 ± 0.17 0.24 ± 0.17 0.23 ± 0.14 
    Change from baseline 0.00 (−0.02 to 0.02) 0.04 (0.02–0.05) 0.04 (0.02–0.06) 0.05 (0.03–0.07) 0.08 (0.06–0.10) 0.08 (0.06–0.09) 
    Change from placebo — 0.03 (0.01–0.06) 0.04 (0.01–0.06) 0.05 (0.02–0.07)* 0.08 (0.05–0.10)* 0.07 (0.05–0.10)* 
ParameterPlaceboSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1,000 mg b.i.d.Sitagliptin 50 mg + metformin 500 mg b.i.d.Sitagliptin 50 mg + metformin 1,000 mg b.i.d.
2-h PPG (mg/dl)       
    n 129 136 141 138 147 152 
    Baseline 276.8 ± 66.7 285.4 ± 82.8 292.7 ± 74.6 283.4 ± 81.8 291.8 ± 84.6 286.9 ± 76.2 
    Week 24 281.3 ± 88.2 233.8 ± 89.5 236.3 ± 70.8 207.0 ± 69.4 196.3 ± 72.5 170.3 ± 58.6 
    Change from baseline 0.3 (−10.4 to 11.0) −51.9 (−62.3 to −41.5) −53.4 (−63.6 to −43.2) −78.0 (−88.3 to −67.6) −92.5 (−102.6 to −82.5) −116.6 (−126.4 to −106.7) 
    Change from placebo — −52.2 (−67.1 to −37.3)* −53.7 (−68.5 to −38.9)* −78.3 (−93.1 to −63.4)* −92.8 (−107.5 to −78.1)* −116.9 (−131.4 to −102.3)* 
Glucose AUC (mg · h−1 · dl−1      
    n 127 133 144 137 149 146 
    Baseline 523.0 ± 109.4 530.2 ± 123.9 538.4 ± 116.0 532.1 ± 125.6 539.9 ± 136.7 530.0 ± 120.7 
    Week 24 533.3 ± 146.9 453.2 ± 135.3 451.3 ± 118.4 401.7 ± 120.4 383.9 ± 114.0 339.0 ± 100.4 
    Change from baseline 6.1 (−11.7 to 23.9) −78.0 (−95.4 to −60.6) −84.4 (−101.1 to −67.7) −130.8 (−147.9 to −113.6) −152.4 (−168.9 to −136.0) −192.3 (−209.0 to −175.7) 
    Change from placebo — −84.2 (−109.1 to −59.3)* −90.5 (−115.5 to −66.1)* −136.9 (−161.6 to −112.2)* −158.6 (−182.8 to −134.3)* −198.5 (−222.8 to −174.1)* 
Insulin AUC (μIU · h−1 · ml−1      
    n 119 117 130 125 126 133 
    Baseline 76.5 ± 52.9 71.2 ± 50.2 80.1 ± 56.4 84.3 ± 53.6 79.0 ± 57.2 74.9 ± 47.2 
    Week 24 75.0 ± 50.3 78.1 ± 49.3 83.1 ± 54.6 82.2 ± 51.4 86.3 ± 55.7 74.5 ± 40.6 
    Change from baseline −1.8 (−7.5 to 3.9) 5.2 (−0.6 to 11.0) 3.6 (−1.9 to 9.1) −0.4 (−6.0 to 5.2) 7.5 (2.0–13.1) −1.1 (−6.5 to 4.4) 
    Change from placebo — 7.0 (−1.2 to 15.1) 5.4 (−2.5 to 13.3) 1.4 (−6.6 to 9.4) 9.4 (1.4–17.3) 0.7 (−7.1 to 8.6) 
C-peptide AUC (ng · h−1 · ml−1125 135 143 138 146 145 
    n       
    Baseline 9.8 ± 4.3 9.8 ± 4.3 10.3 ± 4.1 10.9 ± 4.3 9.9 ± 4.3 10.1 ± 4.1 
    Week 24 9.8 ± 4.2 10.5 ± 4.0 10.2 ± 4.1 10.6 ± 4.1 10.6 ± 4.1 10.4 ± 4.1 
    Change from baseline −0.1 (−0.5 to 0.3) 0.6 (0.2–1.0) 0.0 (−0.4 to 0.4) −0.1 (−0.5 to 0.3) 0.6 (0.2–1.0) 0.3 (−0.1 to 0.7) 
    Change from placebo — 0.7 (0.1–1.3) 0.1 (−0.5 to 0.7) 0.0 (−0.6 to 0.6) 0.7 (0.1–1.3)§ 0.4 (−0.2 to 1.0) 
Insulin AUC/glucose AUC 117 115 128 121 125 130 
    n       
    Baseline 0.16 ± 0.14 0.15 ± 0.12 0.16 ± 0.12 0.18 ± 0.15 0.16 ± 0.14 0.16 ± 0.12 
    Week 24 0.16 ± 0.14 0.19 ± 0.13 0.20 ± 0.15 0.23 ± 0.17 0.24 ± 0.17 0.23 ± 0.14 
    Change from baseline 0.00 (−0.02 to 0.02) 0.04 (0.02–0.05) 0.04 (0.02–0.06) 0.05 (0.03–0.07) 0.08 (0.06–0.10) 0.08 (0.06–0.09) 
    Change from placebo — 0.03 (0.01–0.06) 0.04 (0.01–0.06) 0.05 (0.02–0.07)* 0.08 (0.05–0.10)* 0.07 (0.05–0.10)* 

Data are means ± SD for baseline and week 24 and least-squares mean change (95% CI) for change from baseline or placebo.

*

P ≤ 0.001 for the between-group difference relative to placebo.

P ≤ 0.001 for the between-group difference comparing coadministration and its respective components.

P ≤ 0.05 for the between-group difference relative to placebo.

§

P < 0.05 for the between-group difference comparing coadministration and metformin 500 mg b.i.d.

P ≤ 0.05 for the between-group difference comparing coadministration and its respective components. AUC, area under the curve; PPG, postprandial plasma glucose.